Novo Nordisk began shipping an oral formulation of semaglutide (Wegovy pill) in the U.S.; the company and pharmacies reported immediate dispensing for patients with prescriptions. The oral product mirrors the weight-loss mechanism of weekly Wegovy injections but requires higher oral dosing and step-up titration. Novo listed a $149 cash price while insurers may reduce out-of-pocket cost to roughly $25 per month for some patients under a drug-pricing deal. Clinical trial data cited by the company showed the highest oral dose produced a mean 16.6% weight loss at 64 weeks versus baseline. The oral launch broadens access but raises questions about demand, payer coverage, and long-term cost management as GLP-1s reshape primary care and obesity treatment pathways. Health systems and employers will watch utilization and prior-authorization patterns closely.